Study of IPG1094 in Healthy Participants

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Orally Administered IPG1094 in Healthy Adult Participants

This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, single dose escalation study to evaluate the safety, tolerability, and PK of single dose orally administered IPG1094 in healthy adult participants.

Study Overview

• Status: Recruiting
• Conditions: Safety Issues
• Intervention / Treatment: Drug: IPG1094; Drug: placebo

• Study Type: Interventional
• Enrollment (Anticipated): 46
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Zhang Qi, doctor; Phone Number: 13074800770; Email: qzhang@immunophage.com.cn

Study Locations

• Australia
  • New South Wales
    • Randwick, New South Wales, Australia, 2031
      • Recruiting
      • Scientia Clinical Research Ltd
      • Contact: Christopher Argent; Phone Number: 02 9382 5844; Email: christopher.argent@scienticaclinicalresearch.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Participants must meet all of the following criteria to be included in the study:

Demography

1. Healthy adult male or female participants between 18 and 50 years of age (inclusive).

2. Body weight between 50 and 100 kg (inclusive) and body mass index (BMI) within 18~32 kg/m2 (inclusive).

   Health status

3. In good health as determined by screening tests. Good health is defined as having no clinically relevant abnormalities identified by a detailed medical history, full physical examination (including measurement of blood pressure and pulse rate), 12-lead ECG, and clinical laboratory tests.

   Vital signs (measured after resting for 5 minutes seated position) within normal range, or outside the normal range and not considered clinically significant by the Investigator.

   Standard 12-lead ECG parameters (recorded after resting for 5 minutes in supine position) in the following ranges; corrected QT interval(QTc) (Fridericia algorithm recommended) ≤ 450 ms for males and 470 ms for females, and normal ECG tracing, or abnormal ECG tracing not considered clinically relevant by the Investigator.

   Laboratory parameters demonstrating no clinically significant abnormalities, as determined by the Investigator. A total bilirubin outside the normal range may be acceptable if total bilirubin does not exceed 1.5 × upper limit of normal(ULN) conjugated bilirubin (with the exception of a participant with documented Gilbert syndrome).

4. A negative result on urine drug screen and a repeat negative result on Day -1 (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).

5. Female participants must not be pregnant or breastfeeding and must use an effective contraception method (as described in Section 4.5.4), with the exception of participants who have undergone sterilization in the preceding 3 months, or who are postmenopausal.

   A woman of childbearing potential (WOCBP) must undergo pregnancy testing prior to the first dose of the Investigational Medicinal Product (IMP). The participant must be excluded from the study if the serum pregnancy test is positive.

   A postmenopausal state is defined as 12 months of amenorrhea without an alternative medical cause. In the absence of 12 months of amenorrhea, menopause may be confirmed by follicle stimulating hormone（FSH） measurement (> 40 IU/L or milli-International unit（mIU）/mL).Females on Hormonal Replacement therapy (HRT ), where menopausal status is indeterminate, will be required to use a non-estrogen hormonal contraceptive method if participants wish to continue their HRT during the study. Participants must otherwise discontinue HRT to allow for confirmation of postmenopausal status prior to enrollment in the study.

   Regulation

6. Provide written informed consent prior to undertaking any study-related procedures.
7. Must not be under any administrative or legal supervision or under institutionalization as per a regulatory or juridical order.

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from the study:

Medical history and clinical status

1. Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, musculoskeletal, rheumatological, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness.
2. Frequent severe headaches and/or migraines, recurrent nausea and/or vomiting (defined as vomiting more than twice a month).
3. Made a blood donation of any volume within 2 months prior to the first dose.
4. Symptomatic postural hypotension, irrespective of actual decrease in blood pressure, or asymptomatic postural hypotension with a decrease in systolic blood pressure ≥30 mmHg within 3 minutes of moving from supine to standing position.
5. Presence or history of drug hypersensitivity, or anaphylactic reaction, diagnosed and treated by a physician.
6. Known hypersensitivity to any component of the IMP formulation.
7. History or presence of drug or alcohol abuse (defined as alcohol consumption more than 2 units per day on a regular basis).
8. Regular smoking (defined as more than 5 cigarettes or equivalent per week), or unable to stop smoking during the study. Occasional smokers may be enrolled.

9. Excessive consumption of beverages containing xanthine bases (defined as more than 4 glasses per day).

   Interfering substances

10. Any medication, including St John's Wort, within 14 days prior to administration of the first dose or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, with the exception of hormonal contraception, menopausal hormone replacement therapy, or occasional paracetamol at doses up to 2g/day.
11. Any consumption of grapefruit or products containing grapefruit within 5 days prior to the first dose administration.

12. Any vaccination in the 28 days prior to administration of the first dose.

    General conditions

13. Any participant who, in the judgment of the Investigator, is likely to be non-compliant during the study, or to be unable to cooperate due to language problems or poor mental development.
14. Any participant who enrolled in or participated in any other clinical study involving an investigational medicinal product, or in any other type of medical research within 1 month or within 5 times the elimination half-life prior to administration of the first dose.
15. Any participant who cannot be contacted in the case of an emergency.

16. Any participant who is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff thereof directly involved in conducting the study or any person dependent on (employees or immediate family members) the study site, the Investigator or the Sponsor.

    Biological status

17. Positive result on any of the following tests: hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (HBcAb), anti-hepatitis C virus antibodies (anti-HCV), anti-human immunodeficiency virus 1 and 2 antibodies（anti-HIV1 and anti-HIV2 Ab).
18. Positive alcohol test.
19. Any participant in whom venous blood collection is difficult.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: IPG1094 100mg; Four subjects in this cohort will receive a single dose of IPG1094 100 mg qd and two subjects will receive a single dose of placebo 100mg qd orally. Sentinel subjects (i.e. 1 subject will be dosed with IPG1094 and 1 with placebo before the remainder of the cohort is dosed) will be used in the cohort.	Drug: IPG1094; The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.; Drug: placebo; Matching placebo tablets to IPG1094 50mg and 100mg
EXPERIMENTAL: IPG1094 300mg; Six subjects in this cohort will receive a single dose of IPG1094 300 mg qd and two subjects will receive a single dose of placebo 300mg qd orally.	Drug: IPG1094; The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.; Drug: placebo; Matching placebo tablets to IPG1094 50mg and 100mg
EXPERIMENTAL: IPG1094 600mg; Six subjects in this cohort will receive a single dose of IPG1094 600 mg qd and two subjects will receive a single dose of placebo 600mg qd orally.	Drug: IPG1094; The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.; Drug: placebo; Matching placebo tablets to IPG1094 50mg and 100mg
EXPERIMENTAL: IPG1094 900mg; Six subjects in this cohort will receive a single dose of IPG1094 900 mg qd and two subjects will receive a single dose of placebo 900mg qd orally.	Drug: IPG1094; The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.; Drug: placebo; Matching placebo tablets to IPG1094 50mg and 100mg
EXPERIMENTAL: IPG1094 1200mg; Six subjects in this cohort will receive a single dose of IPG1094 1200 mg qd and two subjects will receive a single dose of placebo 1200 mg qd orally.	Drug: IPG1094; The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.; Drug: placebo; Matching placebo tablets to IPG1094 50mg and 100mg
EXPERIMENTAL: IPG1094 1500mg; Six subjects in this cohort will receive a single dose of IPG1094 1500 mg qd and two subjects will receive a single dose of placebo 1500mg qd orally.	Drug: IPG1094; The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.; Drug: placebo; Matching placebo tablets to IPG1094 50mg and 100mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Occurrence of all adverse events	Evaluation of adverse events	Up to 8 days
RBC	Evaluation of Hematology	Up to 8 days
white blood cell count (WBC)	Evaluation of Hematology	Up to 8 days
platelet count (PLT)	Evaluation of Hematology	Up to 8 days
haemoglobin (HGB)	Evaluation of Hematology	Up to 8 days
mean corpuscular hemoglobin	Evaluation of Hematology	Up to 8 days
mean corpuscular hemoglobin concentration	Evaluation of Hematology	Up to 8 days
Hematocrit	Evaluation of Hematology	Up to 8 days
mean corpuscular volume (MCV)	Evaluation of Hematology	Up to 8 days
absolute differential leukocyte count (eosinophils)	Evaluation of Hematology	Up to 8 days
absolute differential leukocyte count (monocytes)	Evaluation of Hematology	Up to 8 days
absolute differential leukocyte count (lymphocytes)	Evaluation of Hematology	Up to 8 days
absolute differential leukocyte count (basophils)	Evaluation of Hematology	Up to 8 days
absolute differential leukocyte count (neutrophils)	Evaluation of Hematology	Up to 8 days
Temperature (°C )	Evaluation of Vital Signs	Up to 8 days
Respiration rate	Evaluation of Vital Signs	Up to 8 days
Pulse rate	Evaluation of Vital Signs	Up to 8 days
Blood pressure (both systolic and diastolic)	Evaluation of Vital Signs	Up to 8 days
Standard 12-lead ECG - heart rate	Evaluation of Electrocardiograms	Up to 8 days
Standard 12-lead ECG - QTcF	Evaluation of Electrocardiograms	Up to 8 days
Standard 12-lead ECG - PR	Evaluation of Electrocardiograms	Up to 8 days
Standard 12-lead ECG - QRS	Evaluation of Electrocardiograms	Up to 8 days
Standard 12-lead ECG - QT	Evaluation of Electrocardiograms	Up to 8 days
Alanine aminotransferase (ALT)	Evaluation of Serum Chemistry	Up to 8 days
albumin (ALB)	Evaluation of Serum Chemistry	Up to 8 days
alkaline phosphatase (ALP)	Evaluation of Serum Chemistry	Up to 8 days
aspartate aminotransferase (AST)	Evaluation of Serum Chemistry	Up to 8 days
total bilirubin (TBil)	Evaluation of Serum Chemistry	Up to 8 days
Urea	Evaluation of Serum Chemistry	Up to 8 days
calcium (Ca)	Evaluation of Serum Chemistry	Up to 8 days
chloride (Cl)	Evaluation of Serum Chemistry	Up to 8 days
cholesterol (CHO)	Evaluation of Serum Chemistry	Up to 8 days
creatinine (Cr)	Evaluation of Serum Chemistry	Up to 8 days
creatine kinase (CK)	Evaluation of Serum Chemistry	Up to 8 days
glucose (Glu)	Evaluation of Serum Chemistry	Up to 8 days
lactate dehydrogenase (LDH)	Evaluation of Serum Chemistry	Up to 8 days
phosphate (P)	Evaluation of Serum Chemistry	Up to 8 days
potassium (K)	Evaluation of Serum Chemistry	Up to 8 days
sodium (Na)	Evaluation of Serum Chemistry	Up to 8 days
total protein (TP)	Evaluation of Serum Chemistry	Up to 8 days
Prothrombin time (PT)	Evaluation of Serum Coagulation	Up to 8 days
activated partial thromboplastin time (APTT)	Evaluation of Serum Coagulation	Up to 8 days
fibrinogen	Evaluation of Serum Coagulation	Up to 8 days
international normalized ratio (INR)	Evaluation of Serum Coagulation	Up to 8 days
pH	Evaluation of Urinalysis	Up to 8 days
Bilirubin (U-BIL)	Evaluation of Urinalysis	Up to 8 days
glucose (GLU)	Evaluation of Urinalysis	Up to 8 days
urine erythrocytes (U-RBC)	Evaluation of Urinalysis	Up to 8 days
ketones (U-KET)	Evaluation of Urinalysis	Up to 8 days
Urinary leukocyte (U-LEU)	Evaluation of Urinalysis	Up to 8 days
nitrites (U-NIT)	Evaluation of Urinalysis	Up to 8 days
protein (U-PRO)	Evaluation of Urinalysis	Up to 8 days
specific gravity (U-SG)	Evaluation of Urinalysis	Up to 8 days
urobilinogen (URO)	Evaluation of Urinalysis	Up to 8 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum plasma concentration（Cmax）	Pharmacokinetic (PK) parameters after a single oral dose of IPG1094	Blood samples will be collected at 0 h before administration (within 1h prior to administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24, 36, 48, 72, and 96 h after administration.
Time to Cmax (tmax)	Pharmacokinetic (PK) parameters after a single oral dose of IPG1094	Blood samples will be collected at 0 h before administration (within 1h prior to administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24, 36, 48, 72, and 96 h after administration.
Area under the serum concentration-time curve (AUC[0-t]	Pharmacokinetic (PK) parameters after a single oral dose of IPG1094	Blood samples will be collected at 0 h before administration (within 1h prior to administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24, 36, 48, 72, and 96 h after administration.
Area under the serum concentration-infinity curve AUC[0-infinity]	Pharmacokinetic (PK) parameters after a single oral dose of IPG1094	Blood samples will be collected at 0 h before administration (within 1h prior to administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24, 36, 48, 72, and 96 h after administration.
Apparent terminal phase half-life (t1/2)	Pharmacokinetic (PK) parameters after a single oral dose of IPG1094	Blood samples will be collected at 0 h before administration (within 1h prior to administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24, 36, 48, 72, and 96 h after administration.

Collaborators and Investigators

• Sponsor: Nanjing Immunophage Biotech Co., Ltd
• Investigators: Study Director: Wang Jianfei, Nanjing Immunophage Biotech Co., Ltd

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 27, 2021
• Primary Completion (ANTICIPATED): May 18, 2022
• Study Completion (ANTICIPATED): July 30, 2022

Study Registration Dates

• First Submitted: September 16, 2021
• First Submitted That Met QC Criteria: October 27, 2021
• First Posted (ACTUAL): November 8, 2021

Study Record Updates

• Last Update Posted (ACTUAL): November 8, 2021
• Last Update Submitted That Met QC Criteria: October 27, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Keywords: Healthy Volunteers
• Other Study ID Numbers: IPG1094-A001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No